



# Construction of a ceRNA immunoregulatory network related to the development of vascular dementia through a weighted gene coexpression network analysis

Hongshuo Shi<sup>1</sup>, Fengshan Sun<sup>2</sup>, Tiantian Yang<sup>3</sup>, Min Peng<sup>3</sup>, Min Wang<sup>4</sup>, Yiwen Zhang<sup>1</sup>, Yao Wang<sup>1</sup>, Chengda Dong<sup>1</sup>, Zhaojun Yan<sup>5</sup>, Guomin Si<sup>3</sup>, Wenbo Wang<sup>6,7</sup>, Yujie Li<sup>6</sup>

<sup>1</sup>College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China; <sup>2</sup>Department of Encephalopathy, Jinan Traditional Chinese Medicine Hospital, Jinan, China; <sup>3</sup>Department of Traditional Chinese Medicine, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; <sup>4</sup>Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China; <sup>5</sup>Department of Psychosomatic Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China; <sup>6</sup>The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China; <sup>7</sup>Department of Orthopaedics, The 8th Clinical College (Weihai Central Hospital), Qingdao University, Qingdao, China

**Contributions:** (I) Conception and design: H Shi, Y Li, W Wang; (II) Administrative support: F Sun, T Yang; (III) Provision of study materials or patients: M Peng, M Wang; (IV) Collection and assembly of data: Y Zhang, Y Wang; (V) Data analysis and interpretation: C Dong, Z Yan, G Si; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Wenbo Wang; Yujie Li. The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jingba Road 1, Jinan 250001, China. Email: wangwenbo@126.com; liyujie.11@163.com.

**Background:** To date, vascular dementia (VaD) lacks effective treatment in clinical practice. There is also growing evidence that VaD may be closely related to the immune response. The development of high-throughput technology, and the recently discovered group of new mediators called competitive endogenous RNAs (ceRNA), provides a unique opportunity to study the immunomodulation of VaD.

**Methods:** In this study, we used gene expression profiles in the Gene Expression Omnibus (GEO) database to obtain immune-related gene coexpression modules through a weighted gene coexpression network analysis (WGCNA) and gene enrichment analysis. We extracted and merged long non-coding RNA (lncRNA) and microRNA (miRNA) expressions from the GEO database and mapped them with related databases. Subsequently, we used Cytoscape to construct a lncRNA-miRNA-mRNA network, and then we performed an enrichment analysis on the mRNAs in the network to determine their regulatory function. Subsequently, we used an ImmuCellAI immune infiltration analysis and constructed a ceRNA sub-network of related immune cells. Finally, we conducted a gene set enrichment analysis (GSEA) to determine the potential regulatory pathways of the key factors.

**Results:** As a result, we identified the blue module as the key module of immunity and constructed the related CeRNA network. Immune infiltration analysis showed that natural killer T (NKT) cells may be the key immune cells of VaD. Using a Pearson correlation analysis, we identified that *B4GALT1*, *PPP1R3B*, *MICB*, *HHAT*, *DSC2*, *DNA2*, *SCARA3*, and *lncRNA NEAT1* may be the key factors of VaD. Our subsequent GSEA analysis showed that *lncRNA NEAT1* may be regulated by NK cells and toll-like receptors.

**Conclusions:** Our research provides new therapeutic targets for vascular dementia from the immunological perspective for the first time, including *B4GALT1*, *PPP1R3B*, *MICB*, *HHAT*, *DSC2*, *DNA2*, *SCARA3*, and *lncRNA NEAT1*, and our research hopes to provide new treatment options for VaD.

**Keywords:** Competitive endogenous RNAs (ceRNA); vascular dementia (VaD); immune infiltration

Submitted Mar 16, 2021. Accepted for publication Apr 28, 2021.

doi: 10.21037/atm-21-1717

View this article at: <http://dx.doi.org/10.21037/atm-21-1717>

## Introduction

Vascular dementia (VaD) is the second most common type of dementia. It is related to vascular disease, which leads to dysfunction and damage to the cerebrovascular system, including interruption of cerebral blood flow (CBF), brain damage, and eventual cognitive impairment and memory loss (1). In North America and Europe (2), VaD accounts for approximately 15% to 20% of dementia cases, while in Asia and developing countries this proportion has risen to approximately 30% (3). Essentially, VaD is caused by a decrease in the blood supply to the brain (4) and is due to partial or complete occlusion of cerebral perfusion, which is crucial for memory and cognitive processes. VaD reaches its peak in ischemic brain injury (5). In addition to vascular problems, risk factors such as diabetes, age, smoking, and alcohol cannot be ignored (6). Improving vascular endothelial dysfunction and restoring the increase in oxidative stress and neuroinflammation caused by hypoperfusion may provide a potential treatment strategy for preventing the cognitive dysfunction of VaD. From the morphological and structural point of view, the brain of VaD is mainly manifested as a tendency of brain atrophy, and VaD can lead to the decline of brain function, especially the comprehensive decline of intelligence-related functions, and the syndrome will decline to a certain degree. The current treatment for VaD is symptomatic rather than radical, as the number of known drug targets is insufficient to develop VaD therapies. Currently, no drug has been approved by the US FDA for VaD.

In the different forms of central nervous system (CNS) diseases, neuroimmune disorders are common phenomena (7). Recent research indicates that the immune system plays a vital role in VaD, and immune dysfunction has been shown to exist in VaD (8). The CD4<sup>+</sup> CD25<sup>+</sup> FoxP3 regulatory T cells present in VaD patients are significantly reduced (9), and monocytes and natural killer (NK) cells are reduced in VaD, but not in Alzheimer's disease (AD) (10). In addition, the immune response has recently been shown to be an important factor in promoting the development of cerebral small vessel disease, which also affects the progression of VaD (11).

High-throughput technology has recently gained attention, providing an excellent opportunity to identify VaD immune-related biomarkers (12). Long non-coding RNA (lncRNA) is the largest category of ncRNA with a length >200 nucleotides, but it is no significant protein coding potential (13). Although they are not involved in


protein coding, growing evidence shows that lncRNAs have many biological and molecular functions, such as epigenetic regulation, signal transduction, cell differentiation, and immune regulation (14). MicroRNAs (miRNAs, a small family of non-coding RNAs that are important post-transcriptional regulators of gene expression) and lncRNAs are gene regulatory markers that regulate the translation of various proteins and biological processes in health and disease states and play an important role in neurological diseases (15). In 2011, the competitive endogenous RNA (ceRNA) hypothesis proposed attracted much attention (16). In this hypothesis, lncRNA transcripts act as ceRNAs or natural miRNA sponges. They communicate with each other and coregulate mRNAs by competing with shared miRNAs (17). Surprisingly, the amount of research on the association between lncRNAs and VaD is sparse (15).

In this study, we revealed for the first time the molecular mechanism of ceRNA immunoregulation during the progression of VaD. We constructed a VaD-related ceRNA network through a weighted gene coexpression analysis (WGCNA) method to ensure that the nodes were highly interconnected and that the network was highly reliable (18). Then, we performed an immune cell infiltration analysis, constructed a related ceRNA subnet and screened the key factors. Our findings may assist in screening VaD biomarker candidates and therapeutic targets. Our research process is shown in *Figure 1*.

## Methods

### *Microarray data*

From the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo>), which is a public functional genomics data repository, we retrieved and downloaded the VaD microarray expression profile data set (GSE122063 and GSE120584). GSE122063 data, which is the lncRNA and mRNA data set, was collected by researchers at the University of Michigan from the frontal and temporal cortex of VaD, AD, and non-dementia control groups. The total sample size was 136 cases, including 36 cases of VaD and 44 control cases. The data of GSE120584, which is the miRNA data set, was collected from serum samples by researchers at the National Center for Geriatrics in Japan. The sample size was 1,601 cases, including 91 cases of AD, 56 cases of VaD, and 288 control cases. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).



**Figure 1** Flow chart of this research.

### *Data preprocessing and the differential analysis*

We downloaded GPL16699 and GPL21263 files from GEO. We transformed the probe into the corresponding gene symbol according to the annotation information. We used the “GEO2R” online analysis tool in the GEO database to analyze the difference between the two data sets and normalized them. For the mRNA in the chip, we set the threshold as an adjusted P value  $<0.05$ , and for the lncRNA and miRNA in the chip, the threshold was  $|\log_2FC| >0.5$  and adjusted P value  $<0.05$  (19).

### *The weighted gene coexpression network*

We imported the gene expression matrix of the relevant VaD and control groups into the Image GP tool ([http://www.ehbio.com/Cloud\\_Platform/front/#/](http://www.ehbio.com/Cloud_Platform/front/#/)) and constructed a coexpression network of the VaD and control groups’ differentially expressed genes through a WGCNA algorithm. We utilized WGCNA to construct a coexpression module, and screen disease candidate targets. The Pearson correlation coefficient was used to calculate

the linear correlation between each gene pair. We utilized the power function to transform the matrix into a signed adjacency matrix, built a scale-free network, and then transformed it into a topological overlap matrix (TOM). Then, we performed hierarchical clustering of the highly co-expressed genes. Next, we used the dynamic tree cutting algorithm to cut the clustering tree branches to generate modules. The first principal component is the module eigengene (ME), which summarizes the gene expression overall level of each module. MEs are used to assess module-trait associations. Modular Significance (MS) and Gene Significance (GS) are used to calculate the expression patterns of modules related to disease traits. In this study, the dynamic tree cutting algorithm can be used to detect the module, and the minimum module size was 30 (20).

### *Module enrichment analysis*

We used the Enrichr database (<https://maayanlab.cloud/Enrichr/>) to analyze each module of the WGCNA results using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to study

the function of related mRNAs. We then screened out the immune-related modules for the ceRNA network construction.

#### ***Construction of the lncRNA-miRNA-mRNA ceRNA network***

According to the theory that lncRNAs act as miRNA sponges to influence miRNAs and further regulate mRNA expression, we constructed a ceRNA network. We used the starBase database (<http://starbase.sysu.edu.cn/index.php>) and the miRTarbase database (<http://mirtarbase.mbc.nctu.edu.tw/php/index.php>) (21) to search for mRNAs targeted by differential miRNAs. In order to improve the validity of the search results, we included miRNA-targeted mRNAs in all two databases, and then we cross-referenced these mRNAs with the mRNAs of the immune module and performed a correlation test to confirm that the miRNA and mRNA expressions were negatively correlated. We used the starBase (<http://starbase.sysu.edu.cn/index.php>) database to predict the lncRNAs regulated by differential miRNAs by taking the intersection with the differential lncRNAs obtained through the gene chip analysis, and then we performed a correlation test to confirm that the miRNA and mRNA expressions were negatively correlated. In the above process, we used the Cytoscape 3.7.2 visualization to construct a ceRNA network diagram.

#### ***mRNAs of ceRNA network Enrichment analysis***

We used Enrichr to perform the GO and KEGG pathway enrichment analysis on mRNAs in this ceRNA network.

#### ***Immune infiltration analysis***

ImmuCellAI (<http://bioinfo.life.hust.edu.cn/web/ImmuCellAI/>) is a method based on gene set characteristics and is used to accurately appraise the abundance of 18 T cell subgroups and 6 other important immune cells from gene microarray, including B cells, NK cells, and monocyte, macrophage, neutrophil and dendritic cells (DCs) (22). We used this tool to investigate the difference in immune cell infiltration between the VaD and control expression groups.

#### ***Construction of the macrophage-related ceRNA subnetwork***

Pearson's method was used to analyze the correlation coefficient between the value of the NKT cell infiltration and the expression value of mRNAs and lncRNAs ( $|R| > 0.4$ ,

$P < 0.05$ ) in the ceRNA network. Then we analyzed the correlation between the expression values of the lncRNAs and mRNAs in the results, and finally screened the NKT cell ceRNA sub-network construction with an R value  $> 0.4$ .

#### ***Determination of the regulatory pathways of the key factors***

After grouping according to the median expression value of key lncRNAs, we utilized gene set enrichment analysis (GSEA) to analysis the KEGG pathway and GO process of the gene microarray. The standardized enrichment score (NES) was acquired and utilized to identify the key pathways.

#### ***Statistical analysis***

In this study, we used the online analysis tool GEO2R of the GEO database to analyze the difference of related chips, and used WGCNA to analyze the mRNAs matrix. Subsequently, we applied enrichment analysis to related mRNAs, and performed ImmuCellAI immune infiltration analysis on mRNAs. Finally, we used Pearson correlation analysis to analyze the ceRNA network, and finally performed GSEA analysis on the mRNA matrix.


## **Results**

### ***Differentially expressed mRNAs, lncRNAs, and miRNAs in VaD***

We used the online analysis tool GEO2R of the GEO database to analyze the difference between the GSE122063 and GSE120584 data sets. After batch correction, we obtained 6,876 VaD-related differential mRNAs using an adjusted P value  $< 0.05$ , of which 3,178 were upregulated and 3,698 were downregulated. In addition, we also obtained 94 differential miRNAs based on an adjusted P value  $< 0.05$  and  $|\log_2FC| > 0.5$ , of which 89 were upregulated and 5 were downregulated (the related heat map and volcano map are shown in *Figure 2A* and *B*). We also obtained 1,895 differential lncRNAs, of which 925 were upregulated and 970 were downregulated (the related heat map and volcano map are shown in *Figure 2C* and *D*).

### ***Coexpression module construction and immune module identification***

We used the WGCNA algorithm to construct a




**Figure 2** Volcano map and cluster map. (A) Volcano map of miRNAs; (B) cluster map of miRNAs; (C) volcano map of lncRNAs; (D) cluster map of lncRNAs.

coexpression network and modules for the VaD and control group samples. Based on the scale-free topological structure of  $R^2=0.85$ , the Pearson correlation matrix of the gene was transformed into a strengthened adjacency matrix according to the power  $r=6$  (Figure 3A,B). All selected genes were clustered using the dissimilarity measurement method based on the topological overlap matrix (TOM), and the tree was divided into six modules with different colors based on the dynamic tree cutting algorithm (Figure 3C). Then we calculated and plotted the relationship between each module and its corresponding clinical features (Figure 3D). We used the Enrichr database to perform the enrichment analysis of KEGG and GO for each module. The KEGG pathway mainly included staphylococcus aureus infection; leishmaniasis; inflammatory bowel disease (IBD); phagosome; and tuberculosis (Figure 4A). It can be seen that the blue module may be the key module of the immune

response, and the blue module contains a total of 393 mRNAs. Through enrichment analysis, we found that the GO biological process of the blue module mainly included the cytokine-mediated signaling pathway (GO:0019221); neutrophil activation involved in immune response (GO:0002283); neutrophil degranulation (GO:0043312); neutrophil-mediated immunity (GO:0002446); and inflammatory response (GO:0006954) (Figure 4B).

#### Construction of the lncRNA-miRNA-mRNA ceRNA network

We predicted the mRNAs regulated by differential miRNAs through the starBase and miRTarbase databases, including 8,001 in the starBase database and 6,336 in the miRTarbase database. We selected the mRNAs contained in the two databases and intersected the immune-related modules,



**Figure 3** Weighted co-expression network and gene module analysis. (A and B) Soft threshold selection process; (C) clustering dendrogram: each color represents a specific co-expression module. In the colored rows below the tree diagram, the two colored rows represent the original module and the merged module respectively. (D) Heat map of the correlation between vascular dementia (VaD) and the characteristic genes of the module.

and a total of 75 mRNAs were obtained (Figure 4C). In addition, we obtained 46 mRNAs after correlation analysis. We predicted the miRNA-related lncRNAs through the starBase database, and obtained a total of 983 lncRNAs, and then intersected these with the differential lncRNAs to get a total of 16 lncRNAs (Figure 4D). A total of nine lncRNAs were obtained after correlation analysis. We used Cytoscape 3.7.2 to construct the relevant ceRNA network (Figure 5A).


### Enrichment analysis

We used the Enrichr database to perform the enrichment analysis of GO and KEGG for the mRNAs. Through enrichment analysis, we found that the GO biological process of the blue module mainly included regulation of smooth muscle cell proliferation (GO:0048660); positive regulation of cell proliferation (GO:0008284); positive regulation of smooth muscle cell proliferation

(GO:0048661); regulation of establishment of endothelial barrier (GO:1903140); and positive regulation of granulocyte macrophage colony-stimulating factor production (GO:0032725) (Figure 5B). The KEGG pathway mainly included the NF-kappa B signaling pathway; Epstein-Barr virus infection; TNF signaling pathway; legionellosis; and the cytosolic DNA-sensing pathway (Figure 5C).

### Immune cell abundance analysis

ImmuCellAI was used to estimate the abundance of 24 immune cells in the GSE cohort based on microarray data. Among them, CD4\_naive, natural regulatory T (nTreg), iTreg, Th1, natural killer T (NKT) cells, mucosal-associated invariant T cells (MAIT), B cells, monocytes, macrophages, natural killer (NK) cells, neutrophils, and infiltration scores were significantly different between the VaD and control



**Figure 4** Module enrichment analysis and Venn diagram. (A) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis result of blue module; (B) Gene Ontology (GO) analysis result of blue module; (C) Venn plot of mRNAs predicted by differentially expressed miRNAs and blue modules; (D) Venn plot of lncRNAs predicted by differentially expressed miRNAs.

groups. Of these, the difference in NKT cells was the most significant, with the VaD group showing significantly less abundance than the control group ( $P=2.2e-8$ ) (Figure 6A).

#### Construction of the NKT cell-related ceRNA sub-network

We used GSE122063 to identify key genes related to the ImmuCellAI infiltration score of the NKT cells. After correlation analysis, it was found that one lncRNA and 14 mRNA had a strong correlation with NKT cell infiltration (<https://cdn.amegroups.com/static/public/atm-21-1717-1.zip>). The subsequent correlation analysis established the NKT cell ceRNA sub-network constructed with *B4GALT1*, *PPP1R3B*, *MICB*, *HHAT*, *DSC2*, *DNA2*, *SCARA3*, and lncRNA *NEAT1* (Figure 6B), and indicated that lncRNA *NEAT1* may be the key lncRNA identified in our research.


#### GSEA analysis

We applied GSEA analysis to GSE122063 to clarify the regulatory pathways of the key prognostic factors through median grouping of lncRNA *NEAT1* (Figure 7A). It can be seen that these key factors are closely related to immunity, and surprisingly, compared with the lncRNA low expression group, we found that the significantly enriched signaling pathways included the NATURAL\_KILLER\_CELL, and TOLL\_LIKE\_RECEPTOR\_SIGNALING\_PATHWAY (Figure 7B), and GO analysis also shows that lncRNA is closely related to the immune process (Figure 7C).


#### Discussion

VaD refers to a syndrome associated with clinical stroke


A



B




C



**Figure 5** Enrichment analysis of the immune-related ceRNA networks and mRNAs. (A) ceRNA network; (B) Gene Ontology (GO) enrichment analysis of mRNAs in the ceRNA network; (C) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of mRNAs in the ceRNA network.





**Figure 6** Immune infiltration analysis and the correlation between lncRNAs and mRNAs. (A) ImmuCellAI immune infiltration analysis; (B) correlation analysis of lncRNA and mRNA in the ceRNA sub-network of natural killer T (NKT) cells.


or subclinical cerebrovascular injury, which affects at least one cognitive function. The disease is a heterogeneous encephalopathy, accounting for more than 20% of dementia cases (23). Studies have shown that effective treatment of VaD is more challenging than AD. The number of known drug targets is insufficient to develop VaD therapies (4). Therefore, the identification of new therapeutic factors is especially meaningful.

Immune regulation plays an important role in VaD. There is no research on VaD related to NKT cells. However, previous studies have shown that the mechanisms mediated by NKT cells are pro-inflammatory and immune regulatory, including the protective effect of B cell regulation. The production of sex antibodies,


and the destructive effects of suppressing autoimmunity through cytokine production, DC crosstalk, and T-/B-cell interaction (24) is consistent with our immune infiltration results. In this study, we found a CeRNA immunoregulatory network in VaD. Then we established a CeRNA subnet related to NKT cells and identified several key factors, including *B4GALT1*, *PPP1R3B*, *MICB*, *HHAT*, *DSC2*, *DNA2*, and lncRNA *NEAT1*, which could be used as potential therapeutic targets for VaD.

As far as we know, this is the first study using a WGCNA method to construct a lncRNA-related ceRNA network in VaD, to construct its immune-related ceRNA, and to screen the key factors. We first determined the immune-related modules in the WGCNA results through


A



B



C



**Figure 7** The ceRNA network is related to the natural killer T (NKT) cell infiltration score. (A) The NKT cell-related ceRNA sub-network; (B) the Gene Set Enrichment Analysis (GSEA) KEGG in response to lncRNA NEAT1; (C) the GSEA GO in response to lncRNA NEAT1.

enrichment analysis, and constructed the immune response-related ceRNA network, and then enriched the mRNAs in the network to confirm the regulatory function of the network. In the established NKT cell-related ceRNA sub-network, we found that *lncRNA NEAT1* may be the key lncRNA for immune regulation. The research on human *NEAT1* mainly focuses on its oncogene role in various cancers (25). One study has shown that *lncRNA NEAT1* is an epigenetic inhibitor of hippocampal-dependent long-term memory formation and suggests a potential relationship with neuroinflammation (26). Another study showed that the expression of *lncRNA NEAT1* was significantly upregulated in patients with ischemic stroke and aggravated cerebral ischemia-reperfusion (27). In addition, knockdown of *lncRNA NEAT1* inhibits the activity of the pro-inflammatory *AKT/STAT3* pathway, and significantly reduces the differentiation and apoptosis of microglia to the pro-inflammatory (M1) phenotype (28). Furthermore, the sponge mechanism of *miR-24-3p* can exacerbate cerebral ischemia-reperfusion injury (29).

Most of the mRNAs in the ceRNA subnetwork associated with NKT cells may also play an important role in VaD. *B4GALT1* is a member of the b-1 4-galactosyltransferase gene (*B4GALT*) family and plays an important role in many biological events, including morphogenesis, mammalian fertilization, brain development, and cell adhesion (30). This gene may also play an important role in thrombosis. A recent study reported that the expression and activity of *B4GALT1* mRNA in platelets were significantly increased, indicating that the gene was upregulated during late thrombosis and platelet release, thus positioning the gene as a regulatory gene for late thrombosis, possibly at the platelet release level (31). This suggests that the formation of thrombus may have an important influence on the progression of VaD. The protein phosphatase 1 regulatory subunit 3B gene (*PPP1R3B*) is located on chromosome 8p. The previous two GWASs indicate that *PPP1R3B* polymorphism is related to blood lipid traits. In animal studies, a high expression of *PPP1R3B* can affect blood lipid traits. In addition, it was found that *PPP1R3B* variants affect cardiovascular events and atherosclerosis (32), and these factors may cause vascular disease, which in turn may cause VaD. There are relatively few studies on the *MICB* gene related to VaD. The human genome encodes eight functional “stress-inducing ligands”: *MICA*, *MICB*, and *ULBP1-6*. All of these are recognized by a single receptor *NKG2D*, which is expressed on natural killer (NK) cells, cytotoxic T cells, and other T cell subpopulations (33).

*HHAT* is an enzyme in the endoplasmic reticulum, which can palmitate hedgehog protein, and *HHAT* participates in the expression of the sonic hedgehog signaling pathway (34). Hedgehog is involved in almost all planned cell growth and survival mode of vertebrates, and plays an important role in the development of the forebrain and midbrain (35). Desmocollin 3 (*DSC3*) is a member of the desmocollin family (36), and *DSC2* is a transmembrane protein that connects with the other three DSCs to ensure the integrity of myocardial structure and function and is also involved in cell signal transmission and apoptosis (37). The current research on DNA replication helicase/nuclease 2 (*DNA2*) is mainly focused on tumors, and there is currently no research on VaD. *DNA2* is a mediator of genome stability and is required for proper Okazaki fragment maturation, for DSB repair, and for protection of replication forks. In addition, loss or mutation of *DNA2* may inhibit DNA repair pathways in cells (38). Lipid metabolism plays an important role in vascular diseases such as atherosclerosis (39). A study has shown that high levels of receptor class A member 3 (*SCARA3*) methylation are associated with metabolic disorders, including type 2 diabetes and atherosclerosis, and *SCARA3* may contribute to obesity and obesity related metabolic complications in an age-related manner (40). The potential role of these mRNAs in VaD needs to be further explored.

We also performed a GSEA analysis to determine the key regulatory pathways of *lncRNA NEAT1*. Natural killer (NK) cells are a type of cytotoxic lymphocyte that can infiltrate the ischemic brain and exacerbate neuronal cell death (41). Recent research indicates that NK cells play a key role in neurogenesis and cognitive decline during normal brain aging (42). It can be seen that lncRNAs may mediate the cytotoxicity of NK cells to aggravate the progression of VaD, and at the same time, the effect of NKT cells may be inhibited. Toll-like receptor (*TLR*) is an important pattern recognition receptor of the innate immune system, which triggers the inflammatory cascade by recognizing pathogens and related molecular patterns of damage (43). Toll-like receptor 2 (*TLR2*) and *TLR4* are the two most important members of the TLR family. Previous studies have shown that *TLR2* and *TLR4* play a key role in inflammation after ischemic brain injury (44). Generally, *TLR2* and *TLR4* can be activated by a large number of exogenous and endogenous danger signal molecules, and ultimately promote the production of inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (*TNF- $\alpha$* ) (45). Studies have shown that the *TLR4*

pathway induces the production of inflammatory cytokines, which leads to the development of cerebrovascular diseases during VaD (46). In addition, another study also showed that selective destruction of the *TLR2-MyD88* interaction can inhibit inflammation in mice and improve their memory and learning ability (47). Therefore, reducing neuroinflammation by inhibiting the toll-like pathway may be an effective strategy for VaD.

In our research, for the first time, a ceRNA network related to a VaD immune response was constructed, and a sub-network related to NKT cells was constructed. However, our research still has certain limitations. We have not carried out any verification and mechanism experiments. In addition, there has been little research on the role of many of the mRNAs involved in VaD.

## Conclusions

In conclusion, our research innovatively connects ceRNA to immunomodulation in the development of VaD. A decrease of NKT cells, and an increased expression of *B4GALT1*, *PPP1R3B*, *MICB*, *HHAT*, *DSC2*, *DNA2*, *SCARA3*, and lncRNA *NEAT1* may have a significant correlation with the progression of VaD. These results will assist in a better understanding of the immunomodulatory mechanism of VaD from the perspective of ceRNA and may provide candidate therapeutic targets.

## Acknowledgments

**Funding:** This research was funded by the National Natural Science Foundation of China (81800740) and the Natural Science Foundation of Shandong Province (ZR2020MH361).

## Footnote

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/atm-21-1717>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Poh L, Fann DY, Wong P, et al. AIM2 inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia. *Mol Psychiatry* 2020. [Epub ahead of print]. doi:10.1038/s41380-020-00971-5.
2. Wu YT, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. *Lancet Neurol* 2016;15:116-24. Erratum in: *Lancet Neurol* 2016;15:135.
3. Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. *Arterioscler Thromb Vasc Biol* 2019;39:1542-9.
4. Shi H, Dong C, Wang M, et al. Exploring the mechanism of Yizhi Tongmai decoction in the treatment of vascular dementia through network pharmacology and molecular docking. *Ann Transl Med* 2021;9:164.
5. Vijayan M, Reddy PH. Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links. *J Alzheimers Dis* 2016;54:427-43.
6. Li C, Wang Y, Yan XL, et al. Pathological changes in neurovascular units: Lessons from cases of vascular dementia. *CNS Neurosci Ther* 2021;27:17-25.
7. Cacabelos R, Torrellas C, Fernández-Novoa L, et al. Histamine and Immune Biomarkers in CNS Disorders. *Mediators Inflamm* 2016;2016:1924603.
8. Guo Z, Peng X, Li HY, et al. Evaluation of Peripheral Immune Dysregulation in Alzheimer's Disease and Vascular Dementia. *J Alzheimers Dis* 2019;71:1175-86.
9. D'Angelo C, Goldeck D, Pawelec G, et al. Exploratory study on immune phenotypes in Alzheimer's disease and vascular dementia. *Eur J Neurol* 2020;27:1887-94.
10. Busse M, Michler E, von Hoff F, et al. Alterations in the Peripheral Immune System in Dementia. *J Alzheimers Dis* 2017;58:1303-13.
11. Fu Y, Yan Y. Emerging Role of Immunity in Cerebral Small Vessel Disease. *Front Immunol* 2018;9:67.
12. Layton CJ, McMahon PL, Greenleaf WJ. Large-Scale,

- Quantitative Protein Assays on a High-Throughput DNA Sequencing Chip. *Mol Cell* 2019;73:1075-1082.e4.
13. Pierce JB, Feinberg MW. Long Noncoding RNAs in Atherosclerosis and Vascular Injury: Pathobiology, Biomarkers, and Targets for Therapy. *Arterioscler Thromb Vasc Biol* 2020;40:2002-17.
  14. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet* 2009;10:155-9.
  15. Vijayan M, Reddy PH. Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. *J Alzheimers Dis* 2020;75:353-83.
  16. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* 2011;146:353-8.
  17. Kim MS, Pinto SM, Getnet D, et al. A draft map of the human proteome. *Nature* 2014;509:575-81.
  18. Liu Y, Liu N, Liu Q. Constructing a ceRNA-immunoregulatory network associated with the development and prognosis of human atherosclerosis through weighted gene co-expression network analysis. *Aging (Albany NY)* 2021;13:3080-100.
  19. Xu M, Li Z, Yang L, et al. Elucidation of the Mechanisms and Molecular Targets of Sanhuang Xiexin Decoction for Type 2 Diabetes Mellitus Based on Network Pharmacology. *Biomed Res Int* 2020;2020:5848497.
  20. Yin X, Wang P, Yang T, et al. Identification of key modules and genes associated with breast cancer prognosis using WGCNA and ceRNA network analysis. *Aging (Albany NY)* 2020;13:2519-38.
  21. Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for Sequence-Based miRNA Target Prediction: What to Choose? *Int J Mol Sci* 2016;17:1987.
  22. Miao YR, Zhang Q, Lei Q, et al. ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. *Adv Sci (Weinh)* 2020;7:1902880.
  23. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2011;42:2672-713.
  24. Seidel A, Seidel CL, Weider M, et al. Influence of Natural Killer Cells and Natural Killer T Cells on Periodontal Disease: A Systematic Review of the Current Literature. *Int J Mol Sci* 2020;21:9766.
  25. Yu X, Li Z, Zheng H, et al. NEAT1: A novel cancer-related long non-coding RNA. *Cell Prolif* 2017;50:e12329.
  26. Butler AA, Johnston DR, Kaur S, et al. Long noncoding RNA NEAT1 mediates neuronal histone methylation and age-related memory impairment. *Sci Signal* 2019;12:eaaw9277.
  27. Shen S, Ma L, Shao F, et al. Long Non-Coding RNA (lncRNA) NEAT1 Aggravates Cerebral Ischemia-Reperfusion Injury by Suppressing the Inhibitory Effect of miR-214 on PTEN. *Med Sci Monit* 2020;26:e924781.
  28. Ni X, Su Q, Xia W, et al. Knockdown lncRNA NEAT1 regulates the activation of microglia and reduces AKT signaling and neuronal apoptosis after cerebral ischemic reperfusion. *Sci Rep* 2020;10:19658.
  29. Kuai F, Zhou L, Zhou J, et al. Long non-coding RNA THRIL inhibits miRNA-24-3p to upregulate neuropilin-1 to aggravate cerebral ischemia-reperfusion injury through regulating the nuclear factor  $\kappa$ B p65 signaling. *Aging (Albany NY)* 2021;13:9071-84.
  30. Wang B, Wu S, Fang Y, et al. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. *J Cell Mol Med* 2020;24:12032-43.
  31. Giannini S, Lee-Sundlov MM, Rivadeneyra L, et al.  $\beta$ 4GALT1 controls  $\beta$ 1 integrin function to govern thrombopoiesis and hematopoietic stem cell homeostasis. *Nat Commun* 2020;11:356.
  32. Li WJ, Yin RX, Huang JH, et al. Association between the PPP1R3B polymorphisms and serum lipid traits, the risk of coronary artery disease and ischemic stroke in a southern Chinese Han population. *Nutr Metab (Lond)* 2018;15:27.
  33. Schmiedel D, Mandelboim O. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. *Front Immunol* 2018;9:2040.
  34. Rallis A, Navarro JA, Rass M, et al. Hedgehog Signaling Modulates Glial Proteostasis and Lifespan. *Cell Rep* 2020;30:2627-2643.e5.
  35. Agha Z, Iqbal Z, Azam M, et al. Exome sequencing identifies three novel candidate genes implicated in intellectual disability. *PLoS One* 2014;9:e112687.
  36. Cui T, Yang L, Ma Y, et al. Desmocollin 3 has a tumor suppressive activity through inhibition of AKT pathway in colorectal cancer. *Exp Cell Res* 2019;378:124-30.
  37. Iyer VR, Chin AJ. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). *Am J Med Genet C Semin Med Genet* 2013;163C:185-97.
  38. Han Y, Zhang Z, Wang Z, et al. Increased Expression of DNA2 Was Linked to Poor Prognosis in Breast Cancer. *Dis Markers* 2021;2021:8860728.
  39. Zhang Z, Salisbury D, Sallam T. Long Noncoding RNAs

- in Atherosclerosis: JACC Review Topic of the Week. *J Am Coll Cardiol* 2018;72:2380-90.
40. Peng H, Guo Q, Su T, et al. Identification of SCARA3 with potential roles in metabolic disorders. *Aging (Albany NY)* 2020;13:2149-67.
  41. Dou B, Li S, Wei L, et al. Astragaloside IV suppresses post-ischemic natural killer cell infiltration and activation in the brain: involvement of histone deacetylase inhibition. *Front Med* 2021;15:79-90.
  42. Jin WN, Shi K, He W, et al. Neuroblast senescence in the aged brain augments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. *Nat Neurosci* 2021;24:61-73.
  43. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. *J Neuroimmune Pharmacol* 2007;2:297-312.
  44. Wang YC, Lin S, Yang QW. Toll-like receptors in cerebral ischemic inflammatory injury. *J Neuroinflammation* 2011;8:134.
  45. Wang L, Yang JW, Lin LT, et al. Acupuncture Attenuates Inflammation in Microglia of Vascular Dementia Rats by Inhibiting miR-93-Mediated TLR4/MyD88/NF- $\kappa$ B Signaling Pathway. *Oxid Med Cell Longev* 2020;2020:8253904.
  46. Belkhef M, Beder N, Mouhoub D, et al. The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. *J Neuroimmunol* 2018 Jul 15;320:48-57.
  47. Rangasamy SB, Jana M, Roy A, et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. *J Clin Invest* 2018;128:4297-312.
- (English Language Editor: D. Fitzgerald)

**Cite this article as:** Shi H, Sun F, Yang T, Peng M, Wang M, Zhang Y, Wang Y, Dong C, Yan Z, Si G, Wang W, Li Y. Construction of a ceRNA immunoregulatory network related to the development of vascular dementia through a weighted gene coexpression network analysis. *Ann Transl Med* 2021;9(10):858. doi: 10.21037/atm-21-1717